Furthermore, STAT5 upregulates AXL-expression in vitro in primary AML-blasts via activation from cytokines from the bone marrow environment like TPO or GM-CSF, which conveys FLT3 inhibitor-resistance by activating PI3K and RAS/RAF [51, 52]. Here, FLT3 is linked to acute myeloid leukemia.